文献速递泌尿男性生殖肿瘤

美国国家癌症研究所指定癌症中心前列腺癌放疗收费透明度分析

Analysis of Price Transparency via National Cancer Institute-Designated Cancer Centers' Chargemasters for Prostate Cancer Radiation Therapy.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究基于2019年2月美国国家癌症研究所指定癌症中心公开的收费表,分析前列腺癌标准放疗(28次调强放疗)的定价差异。

要点

  • 63家NCI指定癌症中心中,84%(52家)公开了前列腺癌简单调强放疗的收费价格。
  • 收费表描述不统一且与实际支付价关联不明,患者难以据此比价。

核心结论

  • CMS强制公开的医院收费表及其对简单调强放疗的描述并不统一,所列价格变异极大。
  • 所列收费与患者或保险方实际支付价格之间的关联尚不明确,削弱了CMS规则对前列腺癌放疗患者的比价价值。
  • 该研究提示CMS价格透明政策的实施可能不足以让患者估算或比较前列腺癌放疗价格。

研究设计与样本

  • 研究识别了2019年2月美国国家癌症研究所指定癌症中心公开的含价格收费表。
  • 提取用于标准前列腺癌放疗的调强放疗每次收费,并计算28次疗程的平均(标准差)收费。
  • 研究未纳入人类参与者。

主要发现

  • 63家指定医院中,52家(84%)列出了与标准前列腺癌放疗相关的简单调强放疗价格。

临床怎么用

  • 肿瘤内科医生应知晓前列腺癌放疗的医院标价变异极大且常远高于Medicare支付价。
  • 目前收费表描述不统一,不宜直接依据标价向患者估算实际放疗费用或进行跨中心比价。

局限性

  • 仅纳入NCI指定癌症中心,未涵盖其他医院。
  • 仅分析简单调强放疗的收费表价格,未涉及实际支付或保险理赔数据。
  • 收费表描述不统一可能影响价格提取的准确性和可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A January 2019 price transparency mandate by the US Centers for Medicare & Medicaid Services (CMS) allows patients to look up the prices of cancer treatment services at hospitals across the United States. OBJECTIVE: To investigate the value of the CMS price transparency rule in allowing patients with prostate cancer to comparison shop by price for radiation treatment services among National Cancer Institute-designated cancer centers. DESIGN, SETTING, AND PARTICIPANTS: We identified the February 2019 publicly available price-containing chargemasters for National Cancer Institute-designated cancer centers. We isolated the charge per fraction of intensity-modulated radiation therapy used in standard prostate radiation treatment. We then calculated the mean (SD) charges of a 28-fraction course of prostate irradiation at all included hospitals. No human participants were included in this study. MAIN OUTCOMES AND MEASURES: We analyzed the degree of price variation, the association of the mean price to the price paid by Medicare, and the association of the prices with the practice expense geographic practice cost index, as determined by Medicare. RESULTS: Of the 63 designated hospitals, 52 (84%) listed a price for simple intensity-modulated radiation therapy that is associated with standard prostate cancer radiation treatment. For a standard 28-fraction treatment, the charges ranged from $18 368 to $399 056, with a mean of $111 728.80 (10.1 times the price paid by Medicare). There was a weak positive association between price and geographic practice cost index, with an r2 value of 0.13 (P = .008). CONCLUSIONS AND RELEVANCE: The availability of CMS-mandated hospital chargemasters and the descriptors used for simple intensity-modulated radiation therapy are not uniform, and the listed charges are highly variable. The association between listed charges and actual prices paid by patients or insurers is unclear, mitigating the value of the CMS rule for patients with prostate cancer who are receiving radiation therapy. This study suggests that implementation of the CMS price transparency policy may be insufficient to enable patients to estimate or compare prices for prostate cancer radiation treatment.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Agarwal A, Dayal A, Kircher SM, et al. Analysis of Price Transparency via National Cancer Institute-Designated Cancer Centers' Chargemasters for Prostate Cancer Radiation Therapy. JAMA Oncol. 2020. PMID: 31944219. doi:10.1001/jamaoncol.2019.5690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。